Karl Naegler appointed General Partner at Ventech, a team sponsored by Natixis Private Equity

Paris, France, September 8, 2009

Karl Naegler joins Ventech, as a General Partner on September 1, 2009. This appointement enables Ventech to pursue its Internationalizing efforts by complementing its Life Science team.

Prior to Ventech, Karl Naegler worked with Atlas Venture (London and Munich) for close to eight years, where he was instrumental in the formation and financing of several start ups across Europe. He notably worked closely with U3 Pharma, prior to its acquisition by Daiichi Sankyo Co., Ltd. in 2008 and served on the Board of Directors of Nitec Pharma and Lumavita. Previously, he worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg, France.

Karl Naegler, 36 years old, holds a PhD in the area of molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine Berlin. He holds an MSc in Biology from the Free University of Berlin and prepared his thesis at Monash University in Melbourne, Australia. During his successful academic career he contributed to several publications in highly respected scientific journals, including Science and FASEB.

His international background and business driven approach fit very well with the Investment strategy developed by Ventech in that sector. In the Healthcare sector, Ventech mainly focuses on companies where sustainable international syndicates could be put in place and where a partial or complete asset monetization could be expected within a few years. Together with Mounia Chaoui and Laurent Assaraf, Karl Naegler will take care of the several remaining investments to be done in the Healthcare sector. Ventech Capital III has already invested in three Biotech companies: Actogenix (Belgium), Cellerix (Spain) and X2 (Germany) ; and a fourth deal is under completion.


Ventech, sponsored by Natixis Private Equity, is a Venture Capital firm with €365 M assets under management that, for more than a decade, has invested in recently formed companies or start-ups. These investments focus on the Life Science and Information Technology sectors, in France and Europe. Its latest fund Ventech Capital III, a €150 M fund, was closed in late 2007. For more information: www.ventechvc.com